Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779632 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1849729 | 0.86 | RAB9A (0.62) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL4408761 | 0.81 | KMT2A (0.48) | SMN1; SMN2RAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL3097093 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1847760 | 0.80 | USP2 (0.70) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1347033 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5355883 | 0.78 | MAPK1 (0.57) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL3099798 | 0.76 | NPC1 (0.63) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6201733 | 0.76 | NPC1 (0.63) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL485122 | 0.76 | HSP90AA1 (0.71) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324015-B1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-8410137-B2 | Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| EP-2324015-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-aventis (FR) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010012964-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NR3C2, NR1H3, NR1H2 | SMN1; SMN2 2853/4885RAB9A 1481/4885NPC1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.